Lytix Bioharma presents data at ASCO from the first LTX-315 clinical trial.
Sunday June 1st Lytix Biopharma presents results from the first Phase I clinical study with LTX-315 at the 50th annual ASCO (American Society of Clinical Oncology). The results are presented as a poster at the ‘Developmental Therapeutics – Immunotherapy Poster Session’. The poster title is “A Phase I study with LTX-315 – an immunogenic cell death inducer in patients with transdermally accessible tumours”.
ASCO is the largest clinical cancer congress, with participants from all over the world.
The overall conclusions from the study were:
- The main safety issues were primarily dose-related flushing and transient hypotension
- Tumour infiltrating lymphocytes and tumour regression were observed in some patients
- The findings confirms the rationale and potential benefit of LTX-315 as a novel intralesional immunotherapy
- A Phase I/IIa study with LTX-315 is ongoing at four sites in Europe (ClinicalTrials.gov NCT01986426)